Four things to know:
1. Ankylosing spondylitis, also known as radiographic axial spondyloarthritis, affects the spine and pelvic joints.
2. Symptoms of the condition include chronic inflammatory back pain, stiffness as well as impaired mobility and function.
3. The Taltz injection was approved due to the efficacy and safety demonstrated in two randomized, double-blind phase 3 studies featuring 657 patients with ankylosing spondylitis.
4. This is the third FDA approval for Taltz. Previously it was approved for the treatment of adults with plaque psoriasis and for active psoriatic arthritis in adults.
More articles on devices:
FDA grants Fast Track designation for DiscGenics’ cell therapy for disc generation
Aurora Spine posts $3.2M in Q2 revenue: 6 things to know
Dr. Thomas Parisi, patient travel to Mexico for total knee replacement where it costs $18,000 less
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
